Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Surprise US FDA Facility Inspections Resume In India

May 24 2022

• By Derrick Gingery

India China map — The COVID-19 outbreak in China delayed the start of surprise inspections by the FDA. • Source: Shutterstock

Related Content

US FDA Mulls Possibility Of Preannouncing Post-COVID Domestic Surveillance Inspections

Mar 16 2021

US FDA Looks To Resume Unannounced Inspections In India And China

Dec 13 2021

India’s COVID-19 Surge Forced Another Abrupt Stop Of US FDA In-Person Inspections

May 21 2021

US FDA Strengthens Inspection Capabilities With Pandemic Alternatives – And Travel Savings

Apr 25 2022

House Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

Mar 10 2022

US FDA Takes A Scientific Look At Hot-Button Issue Of Unannounced Foreign Inspections

Mar 14 2022

FY 2021 Appropriations Provides FDA Healthy Boost – Plus More COVID-19 Funds

Dec 22 2020

How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era

Nov 14 2021

Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says

Jun 18 2021

Additional Topics

India Asia Pacific China United States Manufacturing Regulation BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.